Risk factors for advanced liver fibrosis in HIV-infected individuals: Role of antiretroviral drugs and insulin resistance

Journal of Viral Hepatitis

Volumn 18, Issue 1, 2011, Pages 11-16

  Blanco, F ^a   Barreiro, P ^a   Ryan, P ^a   Vispo, E ^a   Martin Carbonero L ^a   Tuma, P ^a   Labarga, P ^a   Medrano, J ^a   Gonzalez Lahoz J ^a   Soriano, V ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

antiretroviral drugs; hepatitis C; HIV; insulin resistance; liver fibrosis; transient elastometry

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ADVANCED LIVER FIBROSIS; ALCOHOL ABUSE; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EXPOSURE; FEMALE; HEPATITIS C; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DIDANOSINE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; STAVUDINE;

EID: 78650278763     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01261.x     Document Type: Article

References (31)

1. Török N,. Recent advances in the pathogenesis and diagnosis of liver fibrosis. J Gastroenterol 2008; 43: 315-321. (Pubitemid 351958893)
2. Soriano V, Martín-Carbonero L, García-Samaniego J,. Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis? AIDS 2003; 17: 751-753. (Pubitemid 36521083)
3. Cacoub P, Carrat F, Bédossa P, et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study-ANRS HC02. J Hepatol 2008; 48: 765-773.
4. Larrousse M, Laguno M, Segarra M, et al. Non-invasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007; 46: 304-311. (Pubitemid 350287357)
5. Snyder N, Nguyen A, Gajula L, et al. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin Chim Acta 2007; 381: 119-123. (Pubitemid 46719149)
6. De Lédinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41: 175-179.
7. Vergara S, Macías J, Rivero A, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45: 969-974. (Pubitemid 47580344)
8. Nguyen-Khac E, Capron D,. Non-invasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan). Eur J Gastroenterol Hepatol 2006; 18: 1321-1325. (Pubitemid 44737064)
9. Lanternier F, Roulot D, Bentata M, et al. Risks factors of liver fibrosis in a cohort of intravenous drug users coinfected with HIV and HCV at the HAART era: the role of mixed steatosis. Gastroenterol Clin Biol 2007; 31: 822-827.
10. Schiavini M, Angeli E, Mainini A, et al. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med 2006; 7: 331-337. (Pubitemid 43805694)
11. Bani-Sadr F, Lapidus N, Bedossa P, et al. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 2008; 46: 768-774. (Pubitemid 351321564)
12. Barreiro P, Martín-Carbonero L, Núñez M, et al. Predictors of liver fibrosis in HIV-infected patients with chronic HCV infection: assessment using transient elastometry and the role of HCV genotype 3. Clin Infect Dis 2006; 42: 1032-1039.
13. Verma S, Wang C, Govindarajan S, Kanel G, Squires K, Bonacini M,. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006; 42: 262-270. (Pubitemid 43054201)
14. Tural C, Fuster D, Tor J, et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus co-infected patients. J Viral Hepat 2003; 10: 118-125. (Pubitemid 36359849)
15. Soriano V, Puoti M, García-Gascõ P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22: 1-13. (Pubitemid 350301936)
16. Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-1713. (Pubitemid 37468321)
17. Verma S,. HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction? J Antimicrob Chemother 2006; 58: 496-501. (Pubitemid 44288111)
18. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in HIV and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283-287. (Pubitemid 32702341)
19. Macías J, Mira J, Lõpez-Cortés L, et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther 2006; 11: 839-846. (Pubitemid 44736175)
20. Macías J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18: 767-774. (Pubitemid 38535004)
21. Berenguer J, Bellõn J, Miralles P, et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2008; 46: 137-143. (Pubitemid 351263575)
22. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350. (Pubitemid 40439195)
23. McGovern B, Golan Y, Lopez M, et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 2007; 44: 431-437. (Pubitemid 46147629)
24. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001; 183: 134-137. (Pubitemid 32043052)
25. Bräu N, Salvatore M, Ríos-Bedoya C, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55. (Pubitemid 41772515)
26. Tuyama A, Hong F, Mosoian A, Chen P, Chen B, Fiel I, et al. HIV entry and replication in stellate cells promotes cellular activation and fibrogenesis: implications for hepatic fibrosis in HIV/HCV co-infection. 15th Conference on Retroviruses and Opportunistic Infections. Boston, February 2008 [abstract 57].
27. Blackard J, Sherman K,. HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008; 15: 323-330. (Pubitemid 351473633)
28. Hammer S, Eron J, Reiss P, et al. Antiretroviral treatment ofadult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-570. (Pubitemid 351920631)
29. Sterling R, Contos M, Smith P, et al. Steatohepatitis: risk factors and impact on disease severity in HIV/hepatitis C virus coinfection. Hepatology 2008; 47: 1118-1127.
30. Rodríguez-Torres M, Govindarajan S, Solá R, et al. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol 2008; 48: 756-764.
31. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450. (Pubitemid 38988593)